Yahoo
NasdaqCM - Delayed Quote USD

Cibus, Inc. (CBUS)

1.1800 +0.0400 (+3.51%)
At close: November 6 at 4:00:01 PM EST
Trade Cibus on Coinbase
Chart Range Bar
Loading chart for CBUS
  • Previous Close 1.1400
  • Open 1.1600
  • Bid 1.2900 x 100
  • Ask 1.2200 x 100
  • Day's Range 1.1000 - 1.3399
  • 52 Week Range 1.0900 - 4.1910
  • Volume 163,308
  • Avg. Volume 112,635
  • Market Cap (intraday) 90.186M
  • Beta (5Y Monthly) 1.64
  • PE Ratio (TTM) --
  • EPS (TTM) -1.6200
  • Earnings Date Nov 12, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 14.33
  • Zacks Rating Neutral

Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.

www.cibus.com

118

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CBUS
32.18%
S&P 500 (^GSPC)
7.76%

1-Year Return

CBUS
5.98%
S&P 500 (^GSPC)
9.77%

3-Year Return

CBUS
89.19%
S&P 500 (^GSPC)
68.96%

5-Year Return

CBUS
99.35%
S&P 500 (^GSPC)
57.04%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 994k
Earnings -22.14M
Profit Margin -2,227.87%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-30M
-20M
-10M
0
-3500.0%
-3000.0%
-2500.0%
-2000.0%
-1500.0%

Analyst Insights

View More

Analyst Price Targets

2.00
14.33 Average
1.1800 Current
25.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 3/25/2026
Analyst Jefferies
Rating Action Maintains
Rating Hold
Price Action Raises
Price Target 1.9 -> 3

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -10.22%

  • Return on Equity (ttm)

    -223.16%

  • Revenue (ttm)

    4.35M

  • Net Income Avi to Common (ttm)

    -98.19M

  • Diluted EPS (ttm)

    -1.6200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    20.43M

  • Total Debt/Equity (mrq)

    1,933.93%

  • Levered Free Cash Flow (ttm)

    -52.46M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: